JP2005512518A - 熱ショックタンパク質の使用 - Google Patents

熱ショックタンパク質の使用 Download PDF

Info

Publication number
JP2005512518A
JP2005512518A JP2003532534A JP2003532534A JP2005512518A JP 2005512518 A JP2005512518 A JP 2005512518A JP 2003532534 A JP2003532534 A JP 2003532534A JP 2003532534 A JP2003532534 A JP 2003532534A JP 2005512518 A JP2005512518 A JP 2005512518A
Authority
JP
Japan
Prior art keywords
heat shock
shock protein
protein fragment
hsp70
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003532534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512518A5 (enExample
Inventor
レナー，トーマス
ジョージ ケリー，チャールズ
シン，マハヴィア
ワン，イーフェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Original Assignee
King's College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King's College London filed Critical King's College London
Publication of JP2005512518A publication Critical patent/JP2005512518A/ja
Publication of JP2005512518A5 publication Critical patent/JP2005512518A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003532534A 2001-10-03 2002-10-03 熱ショックタンパク質の使用 Withdrawn JP2005512518A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0123756.9A GB0123756D0 (en) 2001-10-03 2001-10-03 A novel chaperone-type of adjuvant for vaccination - Basic 1
PCT/GB2002/004475 WO2003029289A2 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use

Publications (2)

Publication Number Publication Date
JP2005512518A true JP2005512518A (ja) 2005-05-12
JP2005512518A5 JP2005512518A5 (enExample) 2006-02-02

Family

ID=9923176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003532534A Withdrawn JP2005512518A (ja) 2001-10-03 2002-10-03 熱ショックタンパク質の使用

Country Status (7)

Country Link
US (1) US20060264609A1 (enExample)
EP (1) EP1434794A2 (enExample)
JP (1) JP2005512518A (enExample)
AU (1) AU2002329450A1 (enExample)
CA (1) CA2463404A1 (enExample)
GB (1) GB0123756D0 (enExample)
WO (1) WO2003029289A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151049A (zh) * 2004-06-15 2008-03-26 纽约血液中心有限公司 旋盘尾丝虫的天然产物的佐剂和免疫加强性能
US20090118173A1 (en) * 2006-01-24 2009-05-07 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
CN101801402B (zh) * 2007-07-06 2013-08-28 乌得勒支大学控股有限公司 炎性疾病和自身免疫疾病的治疗和预防
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
US20170260286A1 (en) * 2016-03-10 2017-09-14 The General Hospital Corporation Antigen-Binding Fusion Proteins with Modified HSP70 Domains
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018049118A1 (en) * 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
AU2021357131A1 (en) * 2020-10-09 2023-05-25 Zeria Pharmaceutical Co., Ltd. Novel use of mycobacterium tuberculosis extract
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777890B1 (fr) * 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
GB9930443D0 (en) * 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
EP1209226A3 (en) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
WO2002061113A2 (en) * 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation

Also Published As

Publication number Publication date
WO2003029289A3 (en) 2003-08-28
AU2002329450A1 (en) 2003-04-14
CA2463404A1 (en) 2003-04-10
GB0123756D0 (en) 2001-11-21
EP1434794A2 (en) 2004-07-07
US20060264609A1 (en) 2006-11-23
WO2003029289A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
DE69929310T2 (de) Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
KR100671036B1 (ko) 오스테오프로테게린 리간드 활성을 하향-조절하는 방법
CN101969990B (zh) 增强针对艾美球虫属的免疫反应的组合物和方法
US20210283242A1 (en) Immune-mediated coronavirus treatments
JP5964233B2 (ja) Ｈｐｖにより惹起される疾患の治療用組成物
JP2001503014A (ja) 防御免疫応答を増強するための方法
WO2008046251A1 (fr) Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
JP2022046617A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
US20060264609A1 (en) Use of heat shock proteins
JP2003519668A (ja) 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング
CN116688110A (zh) 犬特应性皮炎的治疗
US8470372B2 (en) Material with immunogenicity
KR100877759B1 (ko) 자궁 경부암 저해용 융합 단백질
CN1639569B (zh) 诱导免疫应答的方法和组合物
JP6466328B2 (ja) ＨＰＶ／ＣｙａＡベースのキメラタンパク質並びにＨＰＶ感染及びＨＰＶ誘導性障害に対する免疫応答の誘導におけるその使用
US7070785B2 (en) Heat shock proteins for use in enhancing cellular factor production
EP1757615B1 (en) Fusion protein for inhibiting cervical cancer
JP6039648B2 (ja) 併用ワクチン
TWI358302B (en) Fusion proteins for inhibiting or preventing hpv i
JP7513303B2 (ja) 腫瘍免疫増強剤、その調製方法および適用
AU783851B2 (en) Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent
WO2002033081A2 (en) Veterinary immunisation vectors comprising nucleic acid sequences encoding variants of non-human c3d polypeptides
JPH06502159A (ja) 無細胞ワクチン
WO2007056304A2 (en) Mutated forms of ny-eso-1 produced in yeast and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050927

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070807